Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) 2015B050501002Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) 2020A0505020003Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology 2013A061401007Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology 2017B030314018Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology 2020B1212060026Guangzhou Municipal Science and Technology Project 201704020073National Natural Science Foundation of China 81873591Natural Science Foundation of Guangdong Province 2022A1515011052Natural Science Foundation of Guangdong Province 2023A1515011805Science and Technology Planning Project of Guangdong Province 2018A050506030
6 · The paper itself
Abstract
IFI16 (the murine homologue is IFI204) is an intracellular double-stranded DNA (dsDNA) pattern recognition receptor (PRR) that plays a crucial role in bridging innate and adaptive immunity. However, its function in dendritic cell (DC) activation and anti-hepatocellular carcinoma (HCC) efficacy remains poorly characterised. This study demonstrates that IFI16 promotes DC maturation, functional activation and antitumor immunity. This effect occurs through activation of the STING-TBK1-IRF3 signalling pathway. Our findings establish IFI16 as a key molecule enabling DCs to sense dsDNA and initiate antitumor responses. Consequently, targeting IFI16 and its downstream STING-TBK1-IRF3 signalling pathway represents a potential therapeutic strategy for hepatocellular carcinoma.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
IFI16/204 Promotes Dendritic Cell Activation and Anti-Hepatocellular Carcinoma Efficacy via the STING-TBK1-IRF3 Signalling Pathway. · full record | OpenQuestion